Extensions

US Patent 12016580, titled "Single insertion delivery system for treating embolism and associated systems and methods," has an anticipated expiration date of January 25, 2039. This date is calculated as 20 years from its earliest priority date, which is January 26, 2018. The patent term can be adjusted by Patent Term Adjustment (PTA) or Patent Term Extension (PTE).

Patent Term Adjustment (PTA) and Patent Term Extension (PTE)
The USPTO does not publicly calculate expiration dates for patents but provides a calculator for estimation. The provided patent information indicates an "Anticipated expiration" date of 2039-01-25. [cite: The "Anticipated expiration" is listed as 2039-01-25.] This typically includes any PTA, which compensates for certain delays by the USPTO during patent prosecution. These delays include:

• Failure to issue a first Office Action or notice of allowance within 14 months of filing.
• Failure to issue an action within four months of an applicant's response.
• Failure to issue the patent within three years of the actual filing date.
• Failure to issue the patent within four months of payment of the issue fee.

The patent information does not explicitly state any awarded PTA or PTE in terms of specific days. However, the listed "Anticipated expiration" date accounts for these adjustments.

Continuation Applications, Divisional Applications, and Related Family Members
US Patent 12016580 is a continuation of U.S. patent application Ser. No. 16/258,344, filed on January 25, 2019, which itself claims the benefit of U.S. Provisional Patent Application No. 62/622,691, filed on January 26, 2018 [cite: The description states: "This application is a continuation of U.S. patent application Ser. No. 16/258,344, filed on Jan. 25, 2019, and titled “SINGLE INSERTION DELIVERY SYSTEM FOR TREATING EMBOLISM AND ASSOCIATED SYSTEMS AND METHODS,” which claims the benefit of U.S. Provisional Patent Application No. 62/622,691, filed on Jan. 26, 2018"].

The patent also lists several priority dates and other versions, indicating a family of related applications:

• Priority to US17/498,642: October 11, 2021 [cite: A priority date is listed as 2021-10-11 for US17/498,642.]
• Priority to US17/865,307: July 14, 2022 [cite: A priority date is listed as 2022-07-14 for US17/865,307.]
• Priority to US17/865,297: July 14, 2022 [cite: A priority date is listed as 2022-07-14 for US17/865,297.]
• Other Version: US20220240959A1 [cite: US20220240959A1 is listed as an "Other version".]
• Priority to US17/978,024: October 31, 2022 [cite: A priority date is listed as 2022-10-31 for US17/978,024.]
• Priority to US18/358,837: July 25, 2023 [cite: A priority date is listed as 2023-07-25 for US18/358,837.]
• Priority to US18/497,249: October 30, 2023 [cite: A priority date is listed as 2023-10-30 for US18/497,249.]
• Priority to US19/011,529: January 6, 2025 [cite: A priority date is listed as 2025-01-06 for US19/011,529.]
• Priority to US19/030,209: January 17, 2025 [cite: A priority date is listed as 2025-01-17 for US19/030,209.]
• Priority to US19/030,673: January 17, 2025 [cite: A priority date is listed as 2025-01-17 for US19/030,673.]

Continuation applications typically pursue additional or different claims from the same disclosed invention as the parent application, without adding new subject matter, and share the same priority date. Divisional applications are filed in response to a USPTO restriction requirement, claiming a distinct invention disclosed but not claimed in the parent application, and are also entitled to the parent's filing date as their priority date. The information provided does not explicitly categorize these priority applications as continuations or divisionals, beyond the initial statement that US12016580B2 is a continuation of US 16/258,344.